QIAGEN announced the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect. Mr. Ebeling joins QIAGEN as part of a process launched by the S ... more
Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement
Offer price increased
Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN.
The amendment provides for an increase from the original offer price of €39.00 to a new price of €43.00 per QIAGEN share in cash, which represents a premium of approximately 35% to the closing price of QIAGEN’s ordinary shares on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the acquisition agreement and Thermo Fisher’s intention to commence the offer. The amendment also provides for a reduction of the minimum acceptance threshold from 75% to 66.67% of QIAGEN’s issued and outstanding ordinary share capital at the end of the acceptance period on August 10, 2020, as well as a USD 95 million expense reimbursement to Thermo Fisher if the minimum acceptance threshold is not met.
The members of QIAGEN’s Supervisory Board and Managing Board have reaffirmed their unanimous support for the offer and their unanimous recommendation that all QIAGEN shareholders accept and tender all of their QIAGEN shares in the offer prior to the end of the acceptance period, which has now been extended to August 10, 2020. Each of the members of the Supervisory Board and Managing Board has tendered or will tender all of their QIAGEN shares in the offer.
Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific, said, “Industry dynamics have changed considerably in the past few months, creating tailwinds and headwinds for our businesses. Both of our companies are playing important roles in helping customers to battle the COVID-19 pandemic. After careful consideration, we’ve decided to increase our offer for QIAGEN to reflect the fair value of the business given the current environment. We remain confident that this transaction will create shareholder value and, importantly, provide meaningful benefits to our customers and society by combining our capabilities to combat infectious diseases and other healthcare issues. We continue to look forward to completing the transaction in the first half of 2021.”
“After carefully considering the updated offer by Thermo Fisher, QIAGEN’s Supervisory Board and Managing Board both unanimously recommend that shareholders accept this offer given that it reflects the improvements in our business performance and future prospects as a result of the coronavirus pandemic,” said Thierry Bernard, chief executive officer of QIAGEN N.V. “The rationale for this strategic step is stronger than ever, especially as the value of molecular testing becomes ever more evident. This combination is designed to enable QIAGEN employees and our portfolio of Sample to Insight solutions to have an even greater impact on society while also delivering significant cash value to our shareholders. We look forward to working closely with Thermo Fisher to successfully complete the transaction.”
QIAGEN shareholders who have already effectively accepted the offer by tendering their shares are not required to take further action in order to receive the increased offer price in accordance with the terms of the offer. Thermo Fisher’s tender offer statement on Schedule TO, including the offer document that is an exhibit thereto, and QIAGEN’s solicitation/recommendation statement on Schedule 14D-9 will be amended to reflect the revised terms of the transaction. The acceptance period is now scheduled to expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on August 10, 2020.
- Thermo Fisher Scientific
QIAGEN N.V. announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed ... more
QIAGEN announced that it has obtained derogation in Germany by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic (“IVD”) for the detection of SARS-CoV-2. At the same time, ... more
Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to ... more
Thermo Fisher Scientific Inc. announced that it has completed its acquisition of FEI Company, Inc. a manufacturer of high-performance electron microscopy, for $107.50 per share in cash, or a total purchase price of approximately $4.2 billion. The completion of the transaction follows the re ... more
Thermo Fisher Scientific Inc. officially opened its new global headquarters at 168 Third Avenue in Waltham, Mass. The company designed and constructed the new 286,000-square-foot facility in accordance with green building rating systems, making it eligible for LEED (Leadership in Energy & E ... more
Aquion, Ion Chromatography, IC, anions, cations conductivity, ion analysis, Dionex, routine analysis, water testing, food and beverage testing, pharmaceutical counterions, water, waste water, ground water more
Ultimate sensitivity & selectivity to meet tomorrow’s standards today ✓ Quality data across workflows for users at all levels of expertise ✓ Confident quantitation – any sample, any matrix, any user more
VPI NeverVent Technology allows source swap and column exchange without breaking the vacuum ✓ New Helium Saver technology: Use one He-bottle up to 3.5 years instead of 5 months ✓ XLXR Detector: Use one calibration curve instead of multiple ones and gain more sensitivity at the s ✓ more
Comprehensive collection of information for clinical/translational/drug monitoring research, forensic testing, and sports antidoping analysis more
Discover instrumental solutions and workflows to meet regulatory demands and hear about latest work done in the area if emerging contaminants. more
Organizations have made significant investments in enterprise and laboratory tools, technologies and solutions to help improve productivity, better manage data/information and optimize their business processes. However, the reality is that most comp more
Patheon Regensburg is a GMP production site, focused on custom manufacturing of investigational materials for pre-clinical and clinical studies. The size of the site offers a familiar, friendly and collegiate atmosphere that specializes in the combined strengths of high-end R&D and producti ... more
- 1Miniaturized Lab-on-a-Chip for real-time Chemical Analysis of Liquids
- 2Organic thin-film sensors for light-source analysis and anti-counterfeiting applications
- 3A new era of early cancer detection with blood test may change cancer screening paradigms
- 4Beckman Coulter Life Sciences acquires Dublin biotech start-up
- 5Less risk, less costs: Portable spectroscopy devices could soon become real
- 6Pumping up the music of molecules
- 7Mobile phone app accurately detects COVID-19 infection in people’s voices with the help of artificial intelligence
- 8Show me your brain scan and I'll tell you how old you really are
- 9Early Detection by Tango
- 10Sensing pressure using paper